Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

Phase 2 Completed 35 enrolled University of Montreal Hospital Centre (CHUM) Canadian Heads of Academic Radiology-GE Healthcare Development Award · collab Centre de Recherche du Centre Hospitalier de l'Université de Montréal · collab Diabetes Québec · collab Radiological Society of North America · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This study is conducted to test the hypothesis that in type 2 diabetic adults with fatty liver who are resistant to metformin, treatment with liraglutide in combination with metformin will cause an absolute reduction in liver fat superior to insulin-metformin treatment within a 3-month period, as measured by magnetic resonance imaging (MRI).

Timeline

Start: 2011-05
Primary completion: 2014-06
Completion: 2014-06

Publications

Tang A, Rabasa-Lhoret R, Castel H, Wartelle-Bladou C, Gilbert G, Massicotte-Tisluck K, Chartrand G, Olivie D, Julien AS, de Guise J, Soulez G, Chiasson JL. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care. 2015 Jul;38(7):1339-46. doi: 10.2337/dc14-2548. Epub 2015 Mar 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	1.8 mg	Subcutaneous
Subject	insulin glargine	Protein / enzyme biologic	10 iu	—

Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications